We used PT2385 in combination with sequential administration of PD-1 blockade followed by TIM-3 blockade, a regimen proposed to overcome adaptive resistance by TIM-3 upregulation following αPD-1 therapy [50] and reported to be efficacious in lung adenocarcinoma models [51]. This evidence concerns the gene HAVCR2 and lung adenocarcinoma.